Dexcom
(Nasdaq: DXCM)
today announced the commercial launch of its next-generation G7 continuous glucose monitor (CGM) in Canada.
The San Diego-based company expects to make its latest CGM technology available to Canadians on Oct. 10, 2023. It covers people with all types of diabetes aged two and older, including those who are pregnant, in the country.
G7 received FDA clearance in December 2022 and Dexcom launched the device in the U.S. in February of this year.
Get the full story at our sister site, Drug Delivery Business News.